Leech therapy for hip osteoarthritis: a randomized pilot trial
Stange R, Moser C, Hopfenmueller W, Uehleke B, Michalsen A (2017) · Forschende Komplementärmedizin · n=36
Study Profile
- Design
- single-center, open-label, randomized pilot trial (Berlin Charité)
- Sample size (n)
- 36
- Intervention
- Two sessions of 5-7 Hirudo medicinalis leeches periarticular hip, 4 weeks apart
- Comparator
- Standard care: paracetamol + physiotherapy for 8 weeks
- Primary endpoint
- Hip-WOMAC pain at week 8
- Primary result
- Hip-WOMAC pain reduction 28% in leech vs 11% in standard care at week 8 (between-group difference, p=0.046)
- Effect size (Cohen's d)
- 0.52
- Follow-up duration
- 16 weeks
Key Findings
- First RCT of hirudotherapy in hip OA — extends knee OA evidence to a deeper joint
- Effect size smaller than knee OA trials — likely reflects deeper joint and harder leech access
- Functional improvement on Lequesne hip index modest but significant
- Adverse events mild — no serious local or systemic events
- Patient satisfaction high despite smaller effect size
Limitations
- Small sample (n=36)
- Open-label
- Periarticular leech application limited by hip soft-tissue depth
- Comparator paracetamol weaker than NSAID — could inflate apparent leech effect
- Pilot — not powered for confirmatory conclusions
Clinical Implications
Stange 2017 hip OA shows that the leech effect extends to hip OA but with smaller magnitude than knee OA. The pragmatic limitation is anatomical: hip joints are deeper and less accessible to leech bites, which sit on the skin and rely on diffusion of salivary compounds. Clinicians can offer hirudotherapy as an adjunct in hip OA but should counsel patients that the response is typically smaller and less consistent than for knee OA.